BioCryst Pharmaceuticals, Inc. (BCRX) 2024 Q2 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good day, and welcome to the BioCryst second quarter 2024 earnings call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to John Bluth at BioCryst. Please go ahead.

    大家好,歡迎參加 BioCryst 2024 年第二季財報電話會議。(接線員指示) 請注意,本活動將被錄音。現在我想把會議交給 BioCryst 的 John Bluth。請開始。

  • John Bluth - Chief Communication Officer

    John Bluth - Chief Communication Officer

  • Thanks, Dave. Good morning, and welcome to BioCryst's second quarter 2024 corporate and financial results conference call. Today's press release and accompanying slides which we'll be referring to, are available on our website. Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Commercial Officer, Charlie Gayer, and Chief R&D Officer, Dr. Helen Thackray. Following our remarks, we'll answer your questions.

    謝謝你,Dave。各位早安,歡迎參加 BioCryst 2024 年第二季公司與財務業績電話會議。我們今天的新聞稿及我們將引用的隨附簡報投影片,可在公司網站取得。今天與我一同出席的有執行長 Jon Stonehouse;財務長 Anthony Doyle;首席商務長 Charlie Gayer,以及研發長 Helen Thackray 博士。在我們發言之後,我們將回答各位的提問。

  • Today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information as well as the company's future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements.

    今天的電話會議將包含前瞻性陳述,包括關於未來結果、未經審計及前瞻性的財務資訊,以及公司未來表現和/或成就的陳述。這些陳述受到已知與未知風險及不確定性的影響,可能導致我們的實際結果、表現或成就與本簡報中明示或暗示的任何未來結果或表現存在重大差異。您不應過度依賴這些前瞻性陳述。

  • For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website. In addition, today's conference call includes non-GAAP pro forma financial measures. For a reconciliation of these non-GAAP measures against the most directly comparable GAAP financial measure, please refer to the earnings press release posted in the Press Releases section of our Investor Relations website at www.biocryst.com. I'd now like to turn the call over to Jon Stonehouse.

    如需更多資訊(包括對我們風險因素的詳細討論),請參閱公司向美國證券交易委員會(SEC)提交的文件,並可於我們網站查閱。此外,今天的電話會議包含非 GAAP 的備考財務衡量指標。如需將這些非 GAAP 指標與最直接可比的 GAAP 財務指標進行調節(reconciliation),請參閱發布於我們投資人關係網站(www.biocryst.com)「新聞稿」區的財報新聞稿。現在我想把電話交給 Jon Stonehouse。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • Thanks, John. Our second-quarter performance with ORLADEYO is nothing short of amazing, especially when you recall great start we had in the first quarter. This performance is due to the confidence we are seeing from our customers since late last year and that continues to build. Physicians who treat HAE in many of their patients are experiencing firsthand how well ORLADEYO works and that they can achieve this control with an oral once-daily therapy, efficacy and convenience.

    謝謝你,John。我們第二季 ORLADEYO 的表現可說是驚人,尤其是回想我們第一季的強勁開局。這樣的表現源自於我們自去年底以來看到客戶信心提升,而且這股信心仍在持續累積。治療許多 HAE 病患的醫師正親身體驗 ORLADEYO 的療效,以及他們能以每日一次的口服療法達到控制,兼具療效與便利性。

  • Many patients are experiencing efficacy similar to what they had on injectable therapy. As a result, halfway through the fourth year since approval, we are experiencing demand as strong as the start of the launch. Amazing. This confidence has also led us to increase our guidance for the year to between $420 million and $435 million. Charlie will provide more details on the quarter and share why the evidence is increasingly clear, we are on a path to $1 billion at peak.

    許多病患所獲得的療效與先前使用注射療法時相近。因此,在核准後進入第四年的中途,我們所看到的需求強勁程度,與上市初期一樣。令人驚嘆。這份信心也促使我們將全年財測上調至 4.20 億至 4.35 億美元。Charlie 將提供更多本季細節,並分享為何證據愈來愈清楚:我們正走在高峰期達到 10 億美元的道路上。

  • I'd also like to give you an update on our pipeline. Remember, our goal with investment is to bring to market our next meaningful therapy to patients living with rare diseases like we did with ORLADEYO. We continue to make great progress overall advancing our programs.

    我也想向各位更新我們的研發管線。請記得,我們投資的目標,是像 ORLADEYO 一樣,將下一個具重大意義的療法帶給罕見疾病患者。我們在推進各項計畫方面整體持續取得良好進展。

  • First, we remain on track to file for approval in younger children down to two years of age with the oral granule formulation of ORLADEYO next year. This is a very important patient population whose parents have been waiting for this therapy. Think about it. If your child is having HAE attacks, the only current treatment is injecting them. Any parent knows how dramatic that is. So to bring a therapy they can sprinkle in a glass of water on soft food is a game changer for these families. We are wrapping up the trial and preparation is in full gear for this filing and launch.

    首先,我們仍按計畫於明年以 ORLADEYO 口服顆粒劑型,向更年幼、最低至 2 歲的兒童提出核准申請。這是一個非常重要的病患族群,他們的父母一直在等待這項療法。想想看。如果您的孩子出現 HAE 發作,目前唯一的治療方式就是為他們注射。任何父母都知道那有多令人煎熬。因此,能提供一種可撒入一杯水中或拌在軟質食物上的療法,對這些家庭而言將是改變遊戲規則的突破。我們正在完成試驗,並已全力投入申請與上市準備工作。

  • Next, I'd like to update you on BCX10013, our oral Factor D inhibitor. We have shared data from the PNH dose-ranging clinical trial with potential partners. There were no [sales]. The drug has been safe and well tolerated at all doses studied. However, while we are seeing some activity in PNH patients, the effect seen was less than other therapies on the market.

    接下來,我想更新 BCX10013(我們的口服 Factor D 抑制劑)的進展。我們已將 PNH 劑量探索臨床試驗的數據分享給潛在合作夥伴。沒有[銷售]。該藥物在所有研究劑量下皆安全且耐受性良好。然而,雖然我們在 PNH 病患身上看到一些活性,但其效果低於市面上其他療法。

  • As a reminder, early this year, we announced that we had planned to stop spending on the program and reduce staff accordingly, while seeking a potential partner. Potential partners have declined to make the additional investment required to evaluate higher doses. Therefore, we will now discontinue development consistent with the plan we described in January.

    提醒各位,今年稍早我們宣布,計畫停止對該專案的支出並相應縮減人力,同時尋求潛在合作夥伴。潛在合作夥伴已婉拒投入評估更高劑量所需的額外投資。因此,我們現在將依照 1 月所描述的計畫,終止該項開發。

  • Regarding the rest of the pipeline, we have two exciting new molecules moving towards the clinic. We remain on track to start dosing healthy volunteers this year with our KLK5 inhibitor BCX17725 for patients living with Netherton syndrome.

    至於其餘研發管線,我們有兩個令人振奮的新分子正邁向臨床階段。我們仍按計畫於今年開始對健康受試者進行給藥,推進我們的 KLK5 抑制劑 BCX17725,用於 Netherton 症候群患者。

  • We are also on track to begin dose-ranging patients in our DME clinical trial next year with the avoralstat. This will likely give us data in patients in both programs by next year to inform us on activity and dose. So exciting progress in both programs. Finally, our complement programs with our bifunctional fusion protein and oral C5 inhibitor are also progressing towards selecting lead candidates.

    我們也按計畫於明年在 avoralstat 的 DME 臨床試驗中,開始對病患進行劑量探索。這很可能讓我們在明年於兩個專案中都取得病患數據,以協助判斷活性與劑量。兩個專案都取得令人振奮的進展。最後,我們的補體相關專案(包含雙功能融合蛋白與口服 C5 抑制劑)也正朝著選定先導候選物(lead candidates)的方向推進。

  • Let me wrap up with two more important points. First, we are committed to accelerating our path to profitability to become independent of the capital markets for funding. Anthony will share more details, but we are well on our way to delivering on that commitment.

    最後我再總結兩個重要重點。第一,我們致力於加速邁向獲利的進程,以便在資金來源上不再依賴資本市場。Anthony 將分享更多細節,但我們正穩步朝著履行這項承諾前進。

  • And second, our impressive performance this quarter and for the first half of this year is a direct reflection of the commitment our employees have to our patients. This was an amazing quarter of performance on many fronts, and I want to thank every BioCryst employee for getting us here and for the momentum they have created to continue this throughout the remainder of the year.

    第二,我們本季以及今年上半年的亮眼表現,直接反映出員工對病患的投入與承諾。這是一個在多個面向都表現出色的季度,我要感謝每一位 BioCryst 員工帶領我們走到今天,並感謝他們所創造的動能,讓我們能在今年剩餘時間持續延續這股勢頭。

  • Now I'd like to turn it over to Charlie to review the ORLADEYO quarterly performance.

    現在我想把時間交給 Charlie,請他回顧 ORLADEYO 本季的表現。

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Thanks, Jon. It was an absolutely great quarter with over $108 million in global revenue against our expectation of $97 million. Demand rate remains strong and was the key driver of our 34% year-over-year revenue growth. New patient prescriptions for the past three quarters continue to equal the high demand we experienced in the very first three quarters of the launch three years ago. But operational improvements made the immediate difference that drove our performance in the quarter.

    謝謝你,Jon。這一季表現非常出色,全球營收超過 1.08 億美元,高於我們原先預期的 9,700 萬美元。需求率仍然強勁,並且是我們營收年增 34% 的主要驅動因素。過去三個季度的新病患處方量,持續維持在三年前上市初期前三個季度所見的高需求水準。不過,是營運面的改善在本季帶來了立竿見影的差異,並推動了我們的表現。

  • The investments in our team that we have described previously are paying off significantly. The percentage of (technical difficulty) [unpaid] therapy, for example, is up nearly 3% since the end of 2023 from 71.5% to 74.4%. This is ahead of our expectations. Of note, we are up to a paid patient rate of 82% among commercially insured patients. Recall that about 60% of our patients are commercial and the paid rate in this segment is up from 79% at the end of 2023 and 72% at the end of 2022.

    我們先前所提到對團隊的投資,正在顯著產生回報。例如,(技術困難)[未付費]治療的比例,自 2023 年底以來上升了將近 3%,從 71.5% 提升至 74.4%。這高於我們的預期。值得注意的是,在商業保險病患中,我們的付費病患比例已達 82%。請記得,我們約 60% 的病患屬於商業保險,而該族群的付費比例已從 2023 年底的 79% 提升,且高於 2022 年底的 72%。

  • This progress makes our long-term expectation to reach 85% paid even more clear. Other aspects, such as increased patient compliance and retention against our Q2 expectations added to the great result and we see these improvements being sustainable.

    這項進展讓我們長期目標達到 85% 付費比例的可見度更高。其他面向,例如病患依從性與留存率高於我們對第二季的預期,也促成了優異成果;而我們認為這些改善具有可持續性。

  • With that base of improving operations, let's move to the long-term demand and overall market opportunity. Patients have long told us that they want a convenient oral route of administration to prevent attacks but they won't compromise on efficacy and nor will their physicians.

    在營運持續改善的基礎上,接下來我們談談長期需求與整體市場機會。病患長期以來一直告訴我們,他們希望有便利的口服給藥途徑來預防發作,但他們不會在療效上妥協,醫師也同樣不會。

  • Our long-term data and real-world evidence are convincing patients and their physicians that both are possible with ORLADEYO, efficacy and convenience. The cornerstones to this motivating message, 91% reduction in attacks versus baseline in our pivotal trial and the growing and consistent body of real-world evidence that reflects the favorable experiences of individual patients and physicians all with one capsule once a day.

    我們的長期數據與真實世界證據,正讓患者及其醫師相信:使用 ORLADEYO 可以同時兼顧療效與便利性。這項激勵人心訊息的基石包括:在我們的關鍵性試驗中,相較基線發作降低 91%;以及日益增加且一致的真實世界證據,反映出個別患者與醫師的良好使用經驗——而這一切都只需每日一次、一顆膠囊。

  • Physicians are increasingly confident that ORLADEYO will be effective as well as convenient for their patients. And physician confidence translates to patient confidence, particularly for the many patients who would prefer oral prophylaxis therapy regardless of their treatment history.

    醫師對 ORLADEYO 對其患者而言既有效又便利的信心正持續提升。而醫師的信心也會轉化為患者的信心,特別是對於許多不論既往治療史如何、都偏好口服預防性治療的患者而言。

  • Slide 8 of today's presentation shows that 52% of all patients starting ORLADEYO to date, switched after having experienced with other HAE prophylaxis therapies, 32% with a history of on-demand treatment only and 17% were treatment naive. Again, regardless of their prior treatment experience, most patients do well.

    今日簡報的第 8 張投影片顯示,截至目前開始使用 ORLADEYO 的所有患者中,52% 是在使用過其他 HAE 預防性治療後轉換而來,32% 只有按需治療史,17% 則為未曾接受治療者。再次強調,不論先前治療經驗如何,多數患者的治療表現都很好。

  • As you can see on slide 10, 61% of prior prophy and 67% of prophy naive patients who start on ORLADEYO and reach paid status stay on therapy for at least a year. What's notable is that that patient retention is similar, whether patients are starting ORLADEYO or injectable prophylaxis, as you can see from a preliminary analysis of claims data on Slide 11.

    如第 10 張投影片所示,在開始使用 ORLADEYO 並達到付費狀態的患者中,既往曾接受預防治療者有 61%、預防治療新手有 67% 會持續治療至少一年。值得注意的是,從第 11 張投影片對理賠資料的初步分析可見,患者留存率相近,無論患者是開始使用 ORLADEYO 或注射型預防治療。

  • This is not surprising, at least to us, based on our internal data and what we hear from patients. But this point is worth repeating. There is no statistical difference in one-year retention for patients starting ORLADEYO, lanadelumab, or C1 inhibitor prophylaxis. I will point out, however, that the one year retention on ORLADEYO of 61% is numerically higher than the other two.

    基於我們的內部數據以及從患者那裡聽到的回饋,這對我們而言並不意外。但這一點值得重申。在開始使用 ORLADEYO、lanadelumab 或 C1 抑制劑預防治療的患者中,一年留存率沒有統計學上的差異。不過我要指出,ORLADEYO 的一年留存率 61% 在數值上高於另外兩者。

  • So why are patients staying on ORLADEYO at such high rates, rates that are comparable to other prophy therapies. Patients have told us individually and in large market research studies that they would prefer to control their attacks with a daily pill. This includes half the patients currently on injectable prophy as you can see from a recent survey of 120 patients shown on slide 12. They shared their (technical difficulty) to switch in that same market research study. No needles, no preparation, freedom to travel, feeling normal and forgetting they have HAE are all part of their dream. ORLADEYO is delivering on that dream.

    那麼,為什麼患者以如此高的比例持續使用 ORLADEYO,且留存率可與其他預防治療相當?患者在個別訪談及大型市場研究中告訴我們,他們更希望用每日一顆藥來控制發作。如第 12 張投影片所示,這也包括目前使用注射型預防治療的患者中有一半,該結果來自近期對 120 位患者的調查。他們也在同一項市場研究中分享了他們(技術困難)轉換治療的情況。不打針、不需準備、可自由旅行、感覺正常、甚至忘記自己有 HAE,都是他們的夢想的一部分。ORLADEYO 正在實現這個夢想。

  • In large -- in results from large surveys of patients taking ORLADEYO, you can see -- that you can see on slide 14, approximately 80% said they are having fewer attacks than they did before starting or on ORLADEYO. And about 75% told us they are having less severe attacks.

    在大型——在針對使用 ORLADEYO 患者的大型調查結果中,你可以看到——如第 14 張投影片所示,約 80% 表示與開始使用 ORLADEYO 之前相比,他們的發作次數更少。約 75% 也告訴我們,他們的發作嚴重程度較低。

  • Overall, about 9 patients and 10 patients told us their attack control was at least as good as it was previously. And yes, those patients who switched from injectable prophylaxis told us the same thing. This is what efficacy and convenience looks like.

    整體而言,約每 10 位患者中有 9 位告訴我們,他們的發作控制至少與先前一樣好。而且,是的,那些從注射型預防治療轉換過來的患者也告訴我們同樣的結果。這就是療效與便利性的樣貌。

  • So what does this lead to? Well, recent market research with large samples of allergists immunologists shown on slide 15 indicates that over 9 and 10 HAE treaters now consider prescribing ORLADEYO for their patients, and over 50% of current prescribers are extremely likely to prescribe again compared to under 30% a year ago. That is a big shift over a year.

    那這會帶來什麼結果?嗯,如第 15 張投影片所示,近期針對大量過敏免疫科醫師樣本的市場研究顯示,現在超過十分之九的 HAE 治療醫師會考慮為其患者開立 ORLADEYO;且目前的處方醫師中,超過 50% 表示極有可能再次開立,相較一年前不到 30%。這在一年內是很大的轉變。

  • Why have they shifted? Because they have seen the evidence. Not only have we shown it to them, but they've also heard the evidence directly from their patients. This increasing enthusiasm from the physicians matches well with the considerable opportunity that remains for ORLADEYO.

    他們為何改變?因為他們看到了證據。不僅我們向他們展示了這些證據,他們也直接從患者那裡聽到了相關證據。醫師日益高漲的熱情,與 ORLADEYO 仍然存在的可觀機會高度契合。

  • For example, the market research on slide 12 shows that three patients out of four patients currently on injectable prophy are willing to switch. We also have updated administrative claims based studies to size the market that you can see on slide 9. Since we first did these studies prior to the ORLADEYO launch, the number of treated HAE patients in the US has grown to 8,500, and the total number of patient of HAE patients has increased to over 11,000.

    例如,第 12 張投影片的市場研究顯示,目前使用注射型預防治療的患者中,有四分之三願意轉換。我們也更新了基於行政理賠資料的研究來估算市場規模,如第 9 張投影片所示。自我們在 ORLADEYO 上市前首次進行這些研究以來,美國接受治療的 HAE 患者數已增至 8,500 人,而 HAE 患者總數已增加至超過 11,000 人。

  • As I described earlier, patients from all segments are benefiting from ORLADEYO with comparable success in treatment outcomes, patient retention and rate of paid therapy. Even with a strong first three years of the launch and the 2,500 prescriptions through the end of 2023, fewer than one in four US HAE patients has tried ORLADEYO. With a high patient desire for oral therapy and the growing physician intent to prescribe, there is way more opportunity in front of us than behind us.

    如我先前所述,各細分族群的患者都正從 ORLADEYO 中受益,且在治療結果、患者留存率與付費治療比例方面的成功程度相當。即便上市前三年表現強勁,且截至 2023 年底累計處方數達 2,500 張,美國 HAE 患者中嘗試過 ORLADEYO 的仍不到四分之一。在患者對口服治療的高度需求,以及醫師開立意願持續提升的推動下,我們面前的機會遠多於身後。

  • Finally, it is also increasingly clear that our global expansion is working. Ex-US sales in the second quarter were $12.4 million, up 51% year-over-year. We recently exceeded 500 patients in Europe and we are already selling ORLADEYO in over 20 countries globally, with many more actively preparing for market authorization, access and launch.

    最後,也愈來愈清楚的是,我們的全球擴張正在奏效。第二季美國以外(ex-US)銷售額為 1,240 萬美元,年增 51%。我們近期在歐洲的患者數已超過 500 人,且 ORLADEYO 已在全球超過 20 個國家銷售,還有更多國家正積極準備取得上市許可、給付准入與上市。

  • To summarize, the operational improvements we saw in Q2 on top of what we saw in Q1 mean that the increasing paid rates and high patient compliance are sustainable, and we are on track toward our long-term goal of 85% paid treatment in the US.

    總結而言,我們在第一季看到的基礎上,第二季的營運改善意味著付費比例的提升與患者高依從性具有可持續性,我們正朝向在美國達成長期目標——85% 付費治療——的軌道前進。

  • In addition, patient and prescriber confidence are growing stronger because both groups are experiencing not just the convenience, but also the efficacy of ORLADEYO. We've been describing a $1 billion in peak global revenue for ORLADEYO for a few years now. The path to that sustainable peak is increasingly clear.

    此外,患者與處方醫師的信心正持續增強,因為兩個族群體驗到的不僅是 ORLADEYO 的便利性,還有其療效。我們數年來一直描述 ORLADEYO 的全球營收峰值可達 10 億美元。通往該可持續峰值的路徑正變得愈發清晰。

  • Now I'll hand the call over to Anthony to describe our financial performance.

    接下來我把電話交給 Anthony,請他說明我們的財務表現。

  • Anthony Doyle - Chief Financial Officer

    Anthony Doyle - Chief Financial Officer

  • Thanks, Charlie. It's very encouraging to see yet another really strong quarter for ORLADEYO. It's is great work for the whole team. You can find a detailed second quarter financials in today's earnings press release, and I'd like to call your attention to a few items. Total revenue for the quarter was $109.3 million and as Charlie said, $108.3 million of that came from ORLADEYO. That's a 34% increase in ORLADEYO revenue over the same quarter last year and ORLADEYO revenues in the past 12 months are over $373 million.

    謝謝,Charlie。看到 ORLADEYO 又一個非常強勁的季度表現,令人非常振奮。這是整個團隊的出色成果。你可以在今日的財報新聞稿中找到第二季財務的詳細資訊,我想請各位特別注意幾個項目。本季總營收為 1.093 億美元,正如 Charlie 所說,其中 1.083 億美元來自 ORLADEYO。這代表 ORLADEYO 營收較去年同期成長 34%,且過去 12 個月 ORLADEYO 營收超過 3.73 億美元。

  • Of the $108.3 million of global ORLADEYO revenue, $95.9 million came from US sales with the remaining $12.4 million or 11.4% coming from ex-US sales. Operating expenses, not including non-cash stock compensation for the quarter were $87.4 million, a decrease of $6.2 million from Q1 of this year and a decrease of $3 million from Q2 of 2023.

    在 ORLADEYO 全球營收 1.083 億美元中,9,590 萬美元來自美國銷售,其餘 1,240 萬美元(或 11.4%)來自美國以外(ex-US)銷售。本季營運費用(不含非現金的股票薪酬)為 8,740 萬美元,較今年第一季減少 620 萬美元,較 2023 年第二季減少 300 萬美元。

  • Full year 2024 guidance for OpEx remains unchanged at between $365 million and $375 million. We achieved an operating profit for the quarter of $21.9 million, excluding non-cash stock comp and an operating profit of $8.8 million, even when including non-cash stock comp, which was $13.2 million for the quarter.

    2024 全年營運費用(OpEx)指引維持不變,介於 3.65 億至 3.75 億美元。本季我們達成營業利益 2,190 萬美元(不含非現金股票薪酬);即使納入非現金股票薪酬(本季為 1,320 萬美元),營業利益仍為 880 萬美元。

  • Cash at the end of the quarter was at $338.1 million, and net cash utilization for the quarter was just $213,000. We had guided to net cash utilization of between $10 million to $12 million per quarter for the remainder of the year. The main driver for the improvement in cash flow for Q2 was the increase in revenue versus forecast of over $11 million. For the remaining two quarters of 2024, I expect net cash utilization to average out at single-digit millions of dollars per quarter. We're even more confident in our guidance of having quarterly positive cash flow late next year and more strong quarters like we saw in Q2 may help us to accelerate that.

    本季季末現金為3.381億美元,而本季淨現金使用量僅為21.3萬美元。我們先前指引今年剩餘期間每季淨現金使用量介於1,000萬至1,200萬美元之間。第二季現金流改善的主要驅動因素,是營收較預測增加超過1,100萬美元。對於2024年剩餘兩季,我預期每季淨現金使用量平均將落在個位數百萬美元。我們對於明年較晚時點達成單季正向現金流的指引更有信心,而若能出現更多像第二季這樣強勁的季度,可能有助於我們加速達成。

  • To be clear, from both an operational and a financial perspective, Q2 was a stellar quarter. Let's also be clear that this is not a one-off or an anomaly. The performance of the commercial team, both in the US and ex-US since the launch of ORLADEYO has been nothing short of terrific. And yes, Q2 overachieved, even our initial expectations.

    明確地說,從營運與財務兩個角度來看,第二季都是非常出色的一季。也同樣要說清楚,這並非一次性的表現或異常現象。自ORLADEYO上市以來,商業團隊在美國及美國以外市場的表現可說是非常卓越。而且沒錯,第二季的表現超出預期,甚至超過我們最初的期待。

  • If asked was this a surprise, I would answer no. I've stopping surprise given what this team has achieved since launch and given the immense success that we have seen patients have while on ORLADEYO to achieve both efficacy and convenience with this best in class drug. Discontinued strength is what gives us the confidence to increase our 2024 revenue guidance for ORLADEYO so significantly to between $420 million and $435 million, a $30 million to $35 million increase in the range and an approximate $100 million increase over last year's total.

    如果問這是否令人意外,我會回答不。鑑於這個團隊自上市以來所達成的成果,以及我們看到患者在使用ORLADEYO時,透過這款同級最佳藥物同時獲得療效與便利性的巨大成功,我已不再感到驚訝。這種持續的強勁表現,讓我們有信心大幅上調ORLADEYO 2024年營收指引至4.20億至4.35億美元,區間上調3,000萬至3,500萬美元,且較去年全年總額約增加1億美元。

  • As another positive, the entirety of that additional $30 million to $35 million is at the lower royalty rate of 7.5%, which would bring the blended royalty rate down by 30 basis points to 50 basis points versus our prior guidance. With OpEx guidance unchanged at flat to last year, we're even more confident about our past profitability with an operating profit for full year this year, EPS and cash flow positivity on a quarterly basis next year and full year EPS positive and cash flow positive in 2026.

    另一個正面因素是,新增的3,000萬至3,500萬美元全部適用於7.5%的較低權利金率,這將使加權平均權利金率較我們先前指引下調30至50個基點。在營業費用(OpEx)指引維持與去年持平不變的情況下,我們對於今年全年達成營業獲利、EPS,以及明年以季度為基礎達成現金流轉正更具信心,並預期在2026年達成全年EPS轉正與現金流轉正。

  • Operator, we'll now open it up for Q&A.

    接線員,我們現在開放問答。

  • Operator

    Operator

  • We will now begin the question and answer session. (Operator Instructions)

    我們現在開始問答環節。(接線員指示)

  • Tazeen Ahmad. Please go ahead. Tazeen Ahmad with Bank of America. Please go ahead. Is your line on mute?

    Tazeen Ahmad。請發言。美國銀行(Bank of America)的Tazeen Ahmad。請發言。您的電話是否靜音?

  • We're going to transition to Jessica Fye with JPMorgan. Please go ahead.

    我們將轉接至摩根大通(JPMorgan)的Jessica Fye。請發言。

  • Unidentified Participant

    Unidentified Participant

  • This is Nick on for Jessica. Congrats on the quarter and thanks for taking our questions. So based on these results, including the updated guidance for ORLADEYO and maintain expectations around operating expenses, can you discuss your level of feeling around if you could reach GAAP operating profits in 2024 and not just full year operating profits, excluding non-cash stock compensation?

    我是代Jessica提問的Nick。恭喜本季表現,也謝謝讓我們提問。基於這些結果,包括更新後的ORLADEYO指引以及維持對營業費用的預期,能否談談你們對於在2024年達成GAAP營業獲利的把握程度?不僅是全年營業獲利(排除非現金的股票薪酬)。

  • Anthony Doyle - Chief Financial Officer

    Anthony Doyle - Chief Financial Officer

  • Yeah, Q2 as it relates to both revenue and our control on operating expenses, like we said, were terrific. And so when we have guided to previously was getting there not including non-cash stock compensation, we're still guiding to that. Is there a chance that we would get there even including the non-cash stock compensation? Absolutely. Just depends on for the remainder of the year revenue and then the offset between that and OpEx. But what I would guide to is our increased confidence of getting there excluding non-cash stock comp.

    是的,第二季在營收以及我們對營業費用的控管方面,如同我們所說,都非常出色。因此,我們先前所指引的「不含非現金股票薪酬即可達成」的目標,我們仍維持該指引。那是否有機會連同非現金股票薪酬也能達成?當然有。這取決於今年剩餘期間的營收,以及營收與OpEx之間的抵銷關係。但我會指引的是:我們對於排除非現金股票薪酬即可達成的信心提高了。

  • Unidentified Participant

    Unidentified Participant

  • Okay. And then within that raised guidance for ORLADEYO, can you just discuss in a bit more detail your underlying assumptions around new patient starts, the percent of patients on paid drug and maybe compliance retention for the remainder of the year and how that changes -- could change versus 1Q, 2Q?

    了解。另外,針對上調後的ORLADEYO指引,能否更詳細說明你們對於今年剩餘期間的新患者起始用藥、付費用藥患者占比,以及依從性/留存率等方面的核心假設?以及這些假設相較於第一季、第二季可能如何變化?

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Sure. Yeah, Nick, we've -- as you know, we've reported very consistent new patient starts, and then the last three quarters have been even stronger, as strong as the first three quarters of the launch. So we would expect the consistent demand, based on all the metrics that I described today.

    當然。是的,Nick,如你所知,我們回報的新患者起始用藥一直非常穩定,而過去三個季度甚至更強,與上市初期前三個季度一樣強勁。因此,基於我今天描述的所有指標,我們預期需求將維持一致。

  • As far as paid rate, like I said, we're ahead of our expectations. We are not expecting major increases for the rest of the year. The goal is to at least hold that consistent with the 74.4% that we were at the end of Q2. And compliance is just really strong. So compliance at this point, if you measure it by the number of treatment days available to the -- your overall patient population, and then the number of drug days basically delivered, we're in the mid-90s at this point, and we would expect that to continue.

    至於付費率,如我所說,我們目前領先於自身預期。我們不預期今年剩餘期間會有大幅提升。目標至少是維持與第二季末74.4%一致的水準。而依從性非常強。因此,就依從性而言,如果以整體患者族群可治療天數,以及實際交付的用藥天數來衡量,目前約在90%中段,我們預期將持續維持。

  • Unidentified Participant

    Unidentified Participant

  • Thanks so much.

    非常感謝。

  • Operator

    Operator

  • Tazeen Ahmad, Bank of America.

    美國銀行(Bank of America)的Tazeen Ahmad。

  • Tazeen Ahmad - Analyst

    Tazeen Ahmad - Analyst

  • Hi, guys. Can you hear me?

    嗨,各位。聽得到我嗎?

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • Yeah.

    聽得到。

  • Tazeen Ahmad - Analyst

    Tazeen Ahmad - Analyst

  • Okay, great. Thank you. Can I ask a question about the pipeline, your focus now another 10 disease? Maybe can you talk about the data that you've collected internally that that gives you confidence in pursuing this particular molecule for this indication and maybe the cadence of data to expect over the next year or so? Thanks.

    好的,太好了。謝謝。我想問一個關於研發管線的問題:你們現在聚焦於另一個罕見疾病?能否談談你們內部收集到哪些數據,讓你們有信心針對這個適應症推進這個分子?以及未來一年左右預期的數據發布節奏?謝謝。

  • Helen Thackray - Chief Research & Development Officer

    Helen Thackray - Chief Research & Development Officer

  • Sure. So let me take that last piece first, the cadences is that we, for [17, 75], we are proceeding into first-in-human this year. And so that's an important milestone to keep in mind for this program. In terms of the data that we have to support that, we have all of the required data to be able to proceed to first human.

    當然。我先回答最後一部分:就節奏而言,針對[17, 75],我們今年將推進至首次人體試驗(first-in-human)。因此,這是此計畫需要記住的一個重要里程碑。至於支持推進的數據,我們已具備所有進入首次人體試驗所需的必要數據。

  • Generally, that includes safety from a non-clinical toxicology perspective as well as data to support the importance of the mechanism for treating the disease and the potential to improve clinical symptoms in patients. So we have non-clinical data for both safety and efficacy that's supportive of proceeding to humans. We also have data around the likely exposure range, and we will be going to first in-human this year.

    一般而言,這包括非臨床毒理學層面的安全性資料,以及支持該作用機制在治療此疾病上重要性的資料,並顯示其有潛力改善患者臨床症狀。因此,我們擁有支持進入人體試驗的非臨床安全性與有效性數據。我們也有關於可能暴露範圍的資料,而我們將在今年進入首次人體試驗。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • Yeah, and Helen and I were in Birmingham this week and we got to see the animal model work that the team is working on. It's an inflammation model, and it was really impressive what we saw the control animals have an inflammation and then the inflammation going down with each higher dose. So the key is that you not only have good drug levels, but the drug levels get to the target, which is the skin and so far so good. So we're hoping we'll see that in humans as well.

    是的,Helen和我這週在伯明翰,我們看到了團隊正在進行的動物模型研究。那是一個發炎模型,我們看到對照組動物有發炎反應,而隨著劑量提高,發炎程度逐步下降,令人印象深刻。所以關鍵不僅是要有良好的藥物濃度,還要讓藥物濃度到達標的部位,也就是皮膚;目前看起來進展良好。因此我們也希望在人類身上能看到同樣的結果。

  • Operator

    Operator

  • Brian Abrahams, RBC Capital Markets.

    RBC資本市場(RBC Capital Markets)的Brian Abrahams。

  • Brian Abrahams - Analyst

    Brian Abrahams - Analyst

  • Hey, good morning. Thanks for taking my questions and congrats on the quarter. I'm wondering if you could maybe elaborate a little bit more on why we saw such a big uptick in the paid drug just on a quarter-over-quarter basis and maybe some of the seasonal trends underlying that versus kind of operational trends?

    嗨,早安。謝謝讓我提問,也恭喜本季表現。我想請教,能否更詳細說明為何付費用藥在本季相較上季出現如此大幅的提升?以及背後是否有一些季節性趨勢因素,相對於營運面的趨勢?

  • And then, can you talk a little bit more about the inputs that went into your resizing of the HAE market and I guess just in terms with the additional 1,000 patients, just kind of wondering if you can talk about the characteristics or anything you've learned about those additional patients who are out there, how accessible they are, what you might need to do to engage them? Thanks.

    另外,能否多談一些你們在重新估算HAE市場規模時所採用的輸入假設?以及就新增的1,000名患者而言,我想了解你們對這些額外患者的特徵或任何新的洞見:他們的可觸及性如何、你們可能需要做些什麼來與他們互動並促進使用?謝謝。

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Hey, Brian. First off, on the uptick in the paid. As I mentioned in my comments and we've talked about this before, we've invested a lot in the team to really make sure that we are helping patients and healthcare providers do everything possible to not only put in kind of a complete start form upfront, all the information that payers want, but then to go through the appeals process when that's necessary. And since we made that investment last year, I think the team is really hitting stride, and that's what's making the difference.

    嗨,Brian。首先,關於已獲給付(paid)比例上升。如同我在評論中提到、而且我們之前也談過,我們在團隊上投入了很多,確保我們能協助病患與醫療照護提供者盡一切可能,不僅在一開始就把一份相對完整的起始申請表(start form)備齊、包含付款方想要的所有資訊,並且在必要時走完申訴(appeals)流程。自從我們去年做了那項投資後,我認為團隊真的進入狀態,而這正是帶來差異的原因。

  • It's not a seasonal factor in Q2 and Q1 is really the seasonal time with the re-authorizations. But now it's just really about every single patient and the -- just the operational improvements that we've made. So I'm really pleased with their progress.

    這不是第二季的季節性因素;第一季才是真正因重新授權(re-authorizations)而出現季節性的時點。但現在重點就是每一位病患,以及我們所做的——各項營運改善。所以我對他們的進展非常滿意。

  • As far as the resizing of the market, we've done this kind of work with claims data regularly and you'll recall that prior to launch we talked about 7,500 diagnosed and treated patients. We knew that there was a larger population of untreated patients, but we were conservative in those initial numbers that we put out.

    至於市場規模的重新估算,我們一直都有定期用理賠(claims)資料做這類工作;你也會記得,在上市前我們談到的是7,500名已診斷且接受治療的病患。我們知道還有更大的未治療病患族群,但我們在當初對外提出的初始數字上採取了較保守的估計。

  • What we're seeing now with ORLADEYO attracting patients from all segments, from prophy switches, from on-demand only, and then also treatment-naive patients, we're attracting all three. And so we redid the numbers. We've seen that the market has grown. We think a good portion of that growth is due to our promotion with ORLADEYO. And so we thought it was time to update the overall.

    現在我們看到ORLADEYO正從各個區隔吸引病患:從預防用藥(prophy)轉換者、僅按需(on-demand only)用藥者,以及治療新手(treatment-naive)病患——三類我們都在吸引。因此我們重新計算了數字。我們看到市場已經成長。我們認為其中相當一部分的成長來自我們對ORLADEYO的推廣。所以我們認為是時候更新整體(市場規模)了。

  • Brian Abrahams - Analyst

    Brian Abrahams - Analyst

  • Got it. Thanks so much for the color, Charlie.

    了解。非常感謝補充說明,Charlie。

  • Operator

    Operator

  • Chris Raymond, Piper Sandler.

    Chris Raymond,Piper Sandler。

  • Chris Raymond - Analyst

    Chris Raymond - Analyst

  • Thanks for taking the question and congrats on the progress. Great to see. Just maybe one question on ORLADEYO, one on the pipeline. So I was kind of struck by your patient activation slide with the market research showing that, essentially three in four patients are willing to switch. Can you maybe give a little bit more color on -- as you sort of distill those patients down, how do you activate those patients? That would seem to be a dynamic that would indicate, certainly understand why your guidance has been raised here, but that there's maybe a little bit more opportunity if you can really convert all those patients. So maybe how many of those do you think are really candidates for activation?

    謝謝讓我提問,也恭喜你們的進展。很高興看到。我可能有一題關於ORLADEYO,一題關於研發管線。我對你們的病患啟動(patient activation)投影片印象很深,市場調查顯示基本上四分之三的病患願意轉換。你能否再多補充一些——當你把這些病患進一步細分後,你們要如何啟動這些病患?這樣的動態似乎顯示——我當然理解為什麼你們上調了指引,但如果你們真的能把那些病患都轉換過來,可能還有更多機會。所以你們認為其中有多少人是真正適合被啟動的候選者?

  • And then maybe just a pipeline question. With respect to the Netherton syndrome program, just maybe talk about why you think a KLK5 inhibitor would be effective in this population? And just looking at some of the other programs that are in this disease, talk about maybe how you look at the differentiation. Thanks.

    另外一題是管線方面。關於Netherton症候群計畫,能否談談你們為什麼認為KLK5抑制劑在這個族群會有效?再看同一疾病中其他正在進行的計畫,也請談談你們如何看待差異化。謝謝。

  • Anthony Doyle - Chief Financial Officer

    Anthony Doyle - Chief Financial Officer

  • I'll start with the question about the patient activation. Yeah, we're thrilled to see that so many patients are willing to switch and so many patients who are on injectable prophylaxis and that that's continued and actually grown throughout the launch.

    我先回答病患啟動的問題。是的,我們很高興看到有這麼多病患願意轉換,尤其是許多正在使用注射型預防治療(injectable prophylaxis)的病患;而且這個趨勢在上市期間持續、甚至還在增加。

  • We have a number of ways that we try to activate them. We have extensive digital marketing, other kind of direct marketing programs to patients. But I'll say the number one way to activate them is to make them aware that ORLADEYO is out there, and then to make sure that their healthcare providers are confident in the product. And what you can see from the data I've shown you today is physicians are increasingly confident, and I think when physicians have that conversation with their patient about all of their treatment options, you combine that with the strong patient desire for oral therapy and the willingness to switch, that is what is going to activate more patients to switch. That's going to be the strongest driver.

    我們有多種方式嘗試啟動他們。我們有大量的數位行銷,以及其他各類直接面向病患的行銷方案。但我想說,啟動他們的第一要務,是讓他們知道ORLADEYO的存在,並確保他們的醫療照護提供者對產品有信心。從我今天展示的數據你可以看到,醫師的信心正在提升;我認為當醫師與病患討論所有治療選項時,再結合病患對口服治療的強烈偏好與轉換意願,這就會促使更多病患轉換。這將是最強的驅動因素。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • Yeah, maybe I'll start and then pass it to you. So it's a great question because we're really excited to bring something forward that actually treats the underlying disease rather than the inflammation and the system, the inflammation due to the disease. But I'll let Helen talk a bit more about it.

    是的,我先說幾句再交給你。這是個很好的問題,因為我們非常期待能推進一個真正治療基礎疾病(underlying disease)的方案,而不是只處理發炎以及——由疾病所引起的系統性發炎。不過我讓Helen再多談一些。

  • Helen Thackray - Chief Research & Development Officer

    Helen Thackray - Chief Research & Development Officer

  • Yeah, thanks, Jon. So KLK5 is dysregulated in Netherton syndrome. That's the cause of the disease. So the KLK5 inhibitor is a way to place the function that's missing and improve the cause of the disease. It’s -- so we believe we have a differentiated product for this for two different reasons. One, we've achieved very, very high potency with our drug and that means that we could potentially deliver a subcutaneous dose and also deliver it on a less frequent basis than is typical for this type of therapy.

    好的,謝謝,Jon。KLK5在Netherton症候群中是失調(dysregulated)的。這就是疾病的成因。因此,KLK5抑制劑是一種補上缺失功能、並改善疾病根本原因的方法。我們相信我們在這方面有差異化的產品,原因有兩點。第一,我們的藥物已達到非常、非常高的效力(potency),這表示我們可能可以用皮下注射(subcutaneous)給藥,並且給藥頻率也可能比這類療法的典型頻率更低。

  • And so two, in terms of the (technical difficulty) important to go back to that KLK5 dysregulation of the cause of the disease. This -- approaching this target means that you don't just affect the cause of the disease in the skin, you're also affecting the downstream inflammation, whereas some other programs that are in the pipeline for this disease are affecting just the downstream inflammation.

    第二,從(技術難度)來看,重要的是回到KLK5失調這個疾病根因。以這個標的切入,代表你不只是影響皮膚上的疾病根因,你也會影響下游的發炎反應;而目前此疾病管線中的一些其他計畫,主要只是在影響下游發炎。

  • So we expect to see healing of the skin and improvement of the disease from that perspective, as well as preventing then the downstream inflammation that causes other effects in the disease.

    因此我們預期會看到皮膚癒合、以及從疾病本身角度的改善,同時也能預防造成其他疾病影響的下游發炎。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • And one of the things you see in rare diseases like this where there's nothing to treat it is there are way more patients than you originally estimated and that's really exciting as well.

    另外,在這類沒有治療方式的罕見疾病中,你常會看到實際病患數遠比原先估計的更多,這也非常令人振奮。

  • Chris Raymond - Analyst

    Chris Raymond - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Gena Wang, Barclays.

    Gena Wang,Barclays。

  • Gena Wang - Analyst

    Gena Wang - Analyst

  • Thank you for taking my questions. And also I wanted to add my congrats on the strong quarter. So I was revised the guidance. Just wondering where do you see the main increase? Would that be mainly from on-demand patients, untreated patient or continue to be from the switch over patient? And then for the pipeline assets, just wondering, will you at some point sharing the preclinical data?

    謝謝讓我提問。也想補一句,恭喜你們這一季表現強勁。你們上修了指引。想請問你們認為主要的增量會來自哪裡?會主要來自按需用藥病患、未治療病患,還是仍主要來自轉換過來的病患?另外,對於管線資產,想請問你們是否會在某個時間點分享臨床前(preclinical)數據?

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • on which program, Gena?

    你指的是哪個計畫,Gena?

  • Gena Wang - Analyst

    Gena Wang - Analyst

  • The lead assets, the pipeline assets, the 17725.

    主力資產、管線資產,那個17725。

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Okay, got it. Gena, I think we've -- what I showed today, we're thrilled that we are getting over 50% of patients from prophylaxis switches and then we're also getting the on-demand patients and even treatment naive.

    好的,了解。Gena,我想——我今天展示的內容是:我們很高興有超過50%的病患來自預防治療轉換(prophylaxis switches),同時我們也吸引到按需用藥病患,甚至治療新手病患。

  • We expect that to continue, and the market research that I showed on slide 12 is specific to patients on injectable prophylaxis. And you can see from that the 50% of the patients have a -- of those patients have a preference, specifically for oral prophylaxis therapy and three out of four -- three out of four of those patients are willing to switch. And so what I would expect is the same dynamics to continue about half the patients coming from prophy and then the other half coming from on-demand and treatment naive.

    我們預期這會持續;而我在第12張投影片展示的市場調查,是針對使用注射型預防治療的病患。你可以看到,其中50%的病患——在那些病患之中——明確偏好口服預防治療(oral prophylaxis therapy),而其中四分之三——四分之三的病患願意轉換。因此我預期同樣的動態會延續:大約一半病患來自預防用藥(prophy),另一半來自按需用藥與治療新手。

  • Anthony Doyle - Chief Financial Officer

    Anthony Doyle - Chief Financial Officer

  • While it's great to see that growth this year and growth next year is going to come from that growth in patient demand, the increase in the guidance for this year, a lot of that's driven by the operational activity that Charlie explained. So it's great to see both things happening simultaneously.

    雖然很高興看到今年的成長,而且明年的成長將來自病患需求的提升,但今年上調指引的增加幅度,有很大一部分是由Charlie所說明的營運作為所驅動。所以很高興看到兩件事同時發生。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • Helen, you want to take the --

    Helen,你要接著回答--

  • Helen Thackray - Chief Research & Development Officer

    Helen Thackray - Chief Research & Development Officer

  • Yeah, so in terms of sharing preclinical data, we would, of course, publish data in the future as we have excellent results for our pipeline programs. In terms of the Netherton syndrome program, Jon mentioned earlier the data that we have in an animal model showing changes in the skin.

    是的,關於分享臨床前數據,我們當然會在未來發表數據,因為我們的研發管線專案有非常出色的結果。就 Netherton 症候群專案而言,Jon 先前提到我們在動物模型中的數據,顯示皮膚出現變化。

  • We also have disease animal model information showing the extreme potency with this molecule. So we would expect to share data supporting both potency and effect. But for the purposes of today, I think it's important to know that we have sufficient information to be ready to proceed to first in human, and we're very excited about this program's potential.

    我們也有疾病動物模型的資訊,顯示這個分子具有極高的效力。因此,我們預期會分享支持效力與作用效果的數據。但就今天而言,我認為重要的是要知道,我們已掌握足夠資訊,準備推進到首次人體試驗(first-in-human),而且我們對這個專案的潛力感到非常興奮。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • Yeah, and we're going to have human data by the end of next year. So you're going to start to get a sense of activity and dose by the end of next year, both in this program and the DME avoralstat program, which is super exciting.

    是的,而且我們會在明年年底前取得人體數據。所以到明年年底,你將開始對活性與劑量有概念,無論是在這個專案或 DME avoralstat 專案上,這都非常令人振奮。

  • Gena Wang - Analyst

    Gena Wang - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • Maury Raycroft, Jefferies.

    Maury Raycroft,Jefferies。

  • Maury Raycroft - Analyst

    Maury Raycroft - Analyst

  • Hi, good morning. I'll add my congrats on the quarter and thanks for taking my question. Just to follow up on the paid patients improvement this quarter, you said you could potentially get to 85% paid patients over the next few years, but it sounds like you're doing better than expected on this front. At this point, are you able to provide more clarity into when you could achieve the 85% of patients on pay track?

    嗨,早安。我也要恭喜你們本季的表現,並感謝你們回答我的問題。我想追問一下本季付費患者比例的改善。你們說未來幾年有機會達到 85% 的付費患者,但聽起來你們在這方面的進展優於預期。在目前這個時間點,你們能否更清楚說明大概何時可以達到 85% 付費患者的目標?

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Hey, Maury. I think the real key with the 85% is that's part of our growth, too, the $800 million in the US as we achieve $1 billion peak sales. We previously mapped out a path to that by 2029, we will tried to get there as quickly as we can. But if we get there by 2029, we will achieve that $1 billion. And based on what we've talked about today, it's increasingly clear that we're going to get there.

    嗨,Maury。我認為 85% 的關鍵在於,這也是我們成長的一部分,也就是當我們達到 10 億美元峰值銷售時,美國市場 8 億美元的那一塊。我們先前規劃的路徑是到 2029 年達成;我們會盡可能加快速度。但如果我們在 2029 年達成,就會實現那 10 億美元。而根據我們今天討論的內容,越來越清楚我們會達成。

  • What I'm particularly excited about it, I noted this in my comments is the fact that we're at 82% paid already for the commercial segment, which is our biggest segment. And it just shows that we're going to get there. It's just it's just a matter of time.

    我特別興奮的是——我在評論中也提到——我們在商業保險族群(這是我們最大的族群)目前付費比例已達 82%。這顯示我們一定會達到目標。只是時間早晚的問題。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • And Charlie, is it fair to say that next year could be a really interesting year with Medicare patients in particular, and we don't want to project what we think will happen, but there's a possibility that we could make real progress there as well as.

    Charlie,我這樣說是否合理:明年對 Medicare 患者而言可能會是非常值得關注的一年?我們不想預測會發生什麼,但也有可能我們在那裡也能取得實質進展。

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Right. There's an opportunity to hopefully get a lot of the Medicare patients have not -- or their copayments, and that's led them to be on free product with the full introduction of the IRA next year and the max out of pocket for patients going to $2,000. That could be an opportunity that creates more affordability and thus more paid patients.

    沒錯。我們有機會讓許多 Medicare 患者——他們先前因自付額(copay)問題而未能負擔,因而使用免費用藥——在明年 IRA 全面導入、且患者年度自付上限降至 2,000 美元後,情況有所改善。這可能帶來更高的可負擔性,進而增加付費患者。

  • Maury Raycroft - Analyst

    Maury Raycroft - Analyst

  • Got it. That's helpful. And just to clarify for the 74.4% for this quarter, you expect that to be consistent for the rest of this year, or could that potentially improve some as well?

    了解。這很有幫助。另外想確認一下,本季 74.4% 的比例,你們預期今年剩餘時間會維持一致,還是也可能再有所改善?

  • Anthony Doyle - Chief Financial Officer

    Anthony Doyle - Chief Financial Officer

  • We will always trying to improve it. The time where we can make the biggest progress is during the big re-authorization season in Q1, and we did a great job in Q1 and then some of that rate job bled into the early part of Q2. The rest of the year will be driven more by new patient prescriptions coming in the opportunity to convert long-term free product over to paid will be less than it was in the first part of the year, kind of the seasonal cycle that we should expect going forward.

    我們會一直努力提升。我們能取得最大進展的時間點通常是在第一季的大型重新授權季(re-authorization season);我們在第一季做得很好,而其中一部分成果也延續到第二季初期。今年其餘時間將更多由新患者處方帶動;把長期免費用藥轉為付費的機會,會比年初少一些——這是我們未來應該預期的季節性循環。

  • Maury Raycroft - Analyst

    Maury Raycroft - Analyst

  • Got it. Okay. Thanks for taking my questions.

    了解。好的。謝謝回答我的問題。

  • Operator

    Operator

  • Stacy Ku, TD Cowen.

    Stacy Ku,TD Cowen。

  • Stacy Ku - Analyst

    Stacy Ku - Analyst

  • Wonderful. Thanks so much for taking our questions, and congratulations on the progress. So we have a few follow-ups. First, I appreciate your detailed market research. Our KOLs and survey also tell us that additional injectable entrance are very unlikely to impact oral prophylactic options in HAE. So curious if Charlie or [Jon] can discuss long term where they expect the oral share to stabilize versus the injectable share. That's the first question.

    太好了。非常感謝你們回答我們的問題,也恭喜你們的進展。我們有幾個追問。首先,我很感謝你們詳盡的市場調研。我們的 KOL 與調查也告訴我們,新增的注射劑進入市場,極不可能影響 HAE 的口服預防性治療選項。因此想請 Charlie 或 [Jon] 討論一下長期而言,你們預期口服市占會如何穩定,相對於注射劑市占會如何變化。這是第一個問題。

  • And then the second question is a question on clinician outreach. So Charlie, can you talk about the progress this year? How many new prescribers are adopting ORLADEYO? And what percentage are still in the early days of a prescribing? Just remind us our goals for this year and what target you might have for next year. And then last, a quick follow-up. Just, can you elaborate a little bit more on the ex-US versus US [split] in Q2? Thanks so much.

    第二個問題是關於臨床醫師觸達(outreach)。Charlie,你能談談今年的進展嗎?有多少新的處方醫師開始採用 ORLADEYO?其中有多少比例仍處於剛開始開立處方的早期階段?也請提醒我們今年的目標,以及你們對明年的目標可能會是什麼。最後再快速追問一下:你能否更詳細說明第二季美國以外(ex-US)與美國的[占比]拆分?非常感謝。

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Sure. So on the long-term oral share, I mean, ORLADEYO obviously is the only oral drug on the market and -- once a day. You really, you can't get better than that. So and we talked about our path to $1 billion and 2,000 paid patients in the US. And so, 2,000 out of over 11,000 total patients, you can imagine ORLADEYO is going to get to at least about 20% share. We'll see what happens with other products in the future, but we're very confident in our overall growth.

    當然。關於長期口服市占,我的意思是,ORLADEYO 顯然是市場上唯一的口服藥,而且是每日一次。你真的很難比這更好。我們也談到達到 10 億美元與在美國達到 2,000 名付費患者的路徑。因此,在總患者數超過 11,000 人的情況下,2,000 人你可以想像 ORLADEYO 至少會達到約 20% 的市占。未來其他產品會如何發展我們再觀察,但我們對整體成長非常有信心。

  • The -- as far as prescribers, we continue to see new prescribers coming on board, and we've talked before about our Tier 1 doctors that cover about 50% of the market, sort of 500 doctors to 600 doctors there. And then the bigger Tier 2 group in Q2, we got equal number of prescriptions from both of those groups. So very -- continues to be very balanced.

    至於處方醫師方面,我們持續看到新的處方醫師加入;我們之前也談過 Tier 1 醫師,約涵蓋 50% 的市場,大概是 500 到 600 位醫師。而在第二季,更大的 Tier 2 群體與 Tier 1 群體帶來的處方數量相當。所以整體來看——仍然非常均衡。

  • And we had a very similar number of new prescribers to what we've seen in recent quarters. And as far as kind of adopters in the Tier 1 group, we're now to the point where over 70% of them have prescribed and we keep chipping away at that number. We may never get to 100% with them, but we're going to get close. And all the metrics we see is doctors across the board intend to do more.

    我們新增處方醫師的人數也與近幾季相近。至於 Tier 1 群體中的採用者(adopters),目前已有超過 70% 曾經開立處方,我們會持續一點一滴提升這個比例。我們可能永遠無法達到 100%,但會非常接近。而我們看到的各項指標顯示,整體而言醫師都打算開立更多。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • Hey, Charlie, on that 30%, can you talk about how things like more prophy medicines come into the market and the noise of prophy going up? Can be an opportunity and the [peak] opportunity as well?

    Charlie,關於那 30%,你能談談像是更多預防用藥(prophy medicines)進入市場、以及預防治療討論熱度上升所帶來的「雜訊」,是否也可能成為機會,甚至是[峰值]機會嗎?

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • That's a great point, Jon brings up. So we have two big opportunities. One, we do expect, of course, other competitors injectable products to launch. One may come as soon as the end of this year. And with that, there's just going to be more conversation around switching patients, more treatment options, maybe lower burden treatment injectable products. And so we're going to take advantage of that because we have the product that patients want with an oral once daily therapy.

    Jon 提到一個很好的觀點。所以我們有兩個很大的機會。第一,我們確實預期其他競爭對手的注射劑產品會上市。其中一個可能最快在今年年底就會推出。隨之而來的是,市場上會有更多關於患者轉換的討論、更多治療選項,可能也會有治療負擔更低的注射劑產品。因此我們會把握這個機會,因為我們提供的是患者想要的產品:每日一次的口服治療。

  • And then peak, that we intend to file next year. That is an opportunity in itself, but also there's the halo effect from that there. It's a genetic disease, their families and their doctors where this may become their first real experience with ORLADEYO and starting with the kids and then they maybe move on to the rest of the family. So both of these are opportunities over the next couple of years for us.

    然後是 peak,我們打算在明年提交申請。這本身就是一個機會,同時也有由此帶來的光環效應。這是一種遺傳性疾病,對於患者的家屬與醫師而言,這可能會成為他們第一次真正接觸 ORLADEYO 的經驗;先從兒童開始,之後他們也可能延伸到家族中的其他成員。因此,這兩者在未來幾年對我們而言都是機會。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • Yeah. So these KOLs that tell us, if it’s not broke, don't fix it, if they've got a pediatric patient on injectable it's going to be pretty hard for them to not want to switch to an oral. So we think that's a real opportunity to have that conversation with them. And then, ex-US, Charlie?

    是的。所以這些 KOL 跟我們說,如果沒壞就別修;如果他們有一位使用注射劑的兒科患者,他們會很難不想改成口服藥。所以我們認為,這是一個與他們進行對話的真正機會。然後,美國以外呢,Charlie?

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Yeah, ex-US, what we see is the same consistent pattern of demands. We see many of the ex-US countries moving increasingly towards prophylaxis. For market access reasons, they may never get to quite the same levels of the US. But we're seeing prophy become the standard of care for patients and ORLADEYO to be growing very strongly and patient retention, too, has been very consistent with what we're seeing in the US. So Europe, Japan, Canada, Eastern Europe, we're starting to launch now with our partners in Latin America, a lot of opportunity and a lot of excitement about ORLADEYO coming to the market.

    是的,美國以外,我們看到的是同樣一致的需求模式。我們看到許多美國以外的國家正愈來愈朝向預防性治療(prophylaxis)。出於市場准入的原因,他們可能永遠無法達到與美國相同的水準。但我們看到預防性治療正在成為患者的標準照護,而 ORLADEYO 的成長非常強勁;患者留存率也與我們在美國看到的情況非常一致。因此在歐洲、日本、加拿大、東歐,我們現在也正與拉丁美洲的合作夥伴開始上市推進;ORLADEYO 進入市場帶來很多機會,也令人非常振奮。

  • Stacy Ku - Analyst

    Stacy Ku - Analyst

  • Wonderful. Thank you.

    太好了。謝謝。

  • Operator

    Operator

  • Jon Wolleben, JMP Securities.

    JMP Securities 的 Jon Wolleben。

  • Jon Wolleben - Analyst

    Jon Wolleben - Analyst

  • Good morning. Congrats and thanks for taking the question. Just a couple more for me on the market sizing update. I'm assuming in that 8,500, you guys gave us that's including acute and prophylactic patients but wondering if you had any sense of reasons why that other 2,600 or so are not being treated? And then do you have any sense today of what percentage of treatment-naive patients are going to ORLADEYO first?

    早安。恭喜,也謝謝讓我提問。我還有幾個關於市場規模更新的問題。我假設你們提到的 8,500 人包含急性與預防性治療患者,但想請問你們是否了解為什麼另外大約 2,600 人沒有接受治療?另外,你們今天是否掌握治療新手(treatment-naive)患者中,有多少比例會先選擇 ORLADEYO?

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Sure, Jon. Of the 8,500, that includes patients that are in HAE specific medicines. So when we do this analysis, we look at all the prophy products. We also look at all the acute -- the modern prophy products, I should say. So ORLADEYO plus the injectables and then the acute therapies. So that's what's included there. You saw the data where we're attracting 17% of ORLADEYO patients launched to date have come from the treatment naive and what that tells us is that that treatment naive group is going to increasingly become a treated group.

    當然可以,Jon。在 8,500 人中,包含正在使用 HAE 特定藥物的患者。所以我們做這個分析時,會看所有的預防性產品。我們也會看所有的急性——我應該說是所有現代的預防性產品。也就是 ORLADEYO 加上注射劑,以及急性治療。所以這些都包含在其中。你也看到數據:截至目前已啟用的 ORLADEYO 患者中,有 17% 來自治療新手;這告訴我們,治療新手族群將會愈來愈多轉變為接受治療的族群。

  • Some of those patients are probably just becoming aware of their disease or their physicians are starting to become more aware about HAE and so again, it may never reach 100% of those patients treated, but we expect more and more of them will be treated and it's a great opportunity to help more patients.

    其中一些患者可能只是剛開始意識到自己的疾病,或是他們的醫師開始更了解 HAE;因此同樣地,這些患者不一定會有 100% 都接受治療,但我們預期會有愈來愈多的人接受治療,而這也是幫助更多患者的一個很好的機會。

  • Jon Wolleben - Analyst

    Jon Wolleben - Analyst

  • Okay, but you don't have a sense from market research or what you're seeing in claims, like, a new patient coming into the system is preferring ORLADEYO or [RO]?

    好的,但你們沒有從市場研究或理賠資料中看到,例如,新進入系統的患者更偏好 ORLADEYO 或[RO]?

  • Charles Gayer - Chief Commercial Officer

    Charles Gayer - Chief Commercial Officer

  • Yeah, I knew I was missing one part of your question. We do, ORLADEYO, we have at least 50% of those patients in our market research get ORLADEYO first before other prophylaxis products.

    是的,我就知道我漏掉了你問題的一部分。我們有的;在我們的市場研究中,至少有 50% 的這些患者會先使用 ORLADEYO,之後才使用其他預防性產品。

  • Jon Wolleben - Analyst

    Jon Wolleben - Analyst

  • That's helpful. Thanks, Charlie.

    這很有幫助。謝謝,Charlie。

  • Operator

    Operator

  • Serge Belanger, Needham & Company.

    Needham & Company 的 Serge Belanger。

  • Serge Belanger - Analyst

    Serge Belanger - Analyst

  • Hi, good morning, and congrats on another solid ORLADEYO quarter. First one, given the nice growth we've seen over the first half of 2024, can you tell us a little bit about where you are in terms of market share in the market?

    嗨,早安,也恭喜 ORLADEYO 又交出一個穩健的季度表現。第一個問題,鑑於我們在 2024 年上半年看到的良好成長,你能否跟我們談談你們目前在市場中的市占率大概在哪裡?

  • And then maybe for Charlie, regarding the prescribers survey, we've seen a pretty drastic increase in the likelihood of prescribing year-over-year. Just curious, what do you think drove that increase over such a short period of time? And if I'm not mistaken, you've conducted a survey, I think, every year. Just curious how it is, how predictive it is for future use and uptake of ORLADEYO? Thanks.

    然後也許給 Charlie:關於處方醫師調查,我們看到年比年處方意願大幅提升。想請教你認為是什麼在這麼短的時間內推動了這個提升?如果我沒記錯,你們應該每年都做一次調查。也想了解它對 ORLADEYO 未來使用與採用(uptake)的預測性有多高?謝謝。

  • Anthony Doyle - Chief Financial Officer

    Anthony Doyle - Chief Financial Officer

  • Sure. As far as share goes, Serge, I'll point you back to the 2,500 prescriptions we had at the end of last year. Some of those, of course, are repeat patients who had dropped off and come back. But I think that's a pretty good mark -- marker roughly of where we are. So depending on how you want to do the math, either of treated patients or if the total market, we're probably nearing 20% market share, roughly a little bit below that, but growing very strongly.

    好的。就市占率而言,Serge,我會請你回頭看我們去年底的 2,500 張處方。當然,其中有一些是曾經停用又回來的重複患者。但我認為那大致上是一個相當不錯的指標——大概反映了我們目前的位置。所以看你想怎麼算,無論是以已治療患者或以整體市場來看,我們大概接近 20% 的市占率,約略略低於 20%,但成長非常強勁。

  • And then as far as kind of the indicators of increased prescribing and the physician confidence, I think it's what I said in my remarks, they're just -- they're experiencing, they're learning more about the data and they're seeing it in their patients. So I think the best way for a physician to learn about this drug is to trial in their patients and see how well the patients respond. And that's why of current prescribers now 52% of them say they are extremely likely to prescribe more because they are seeing the response in their patients.

    至於處方增加與醫師信心提升的指標,我想就如我在發言中所說——他們正在親身體驗,也更了解數據,並且在自己的患者身上看到效果。所以我認為,醫師了解這個藥物的最佳方式,就是在自己的患者身上試用並觀察患者反應有多好。這也是為什麼目前的處方醫師中,有 52% 表示他們「極有可能」開出更多處方,因為他們正在看到患者的反應。

  • And we do these surveys every quarter and we always ask physicians, what are you going to treat your patients with over the next 12 months? And what we've seen over the last year is that the drug they seek to grow over the next 12 months is ORLADEYO. That is where they see the most growth in the marketplace. And I think it's because of what they're seeing with the results in their patients.

    而且我們每一季都會做這些調查,並且總是問醫師:未來 12 個月你打算用什麼來治療你的患者?我們在過去一年看到的是,他們希望在未來 12 個月成長的藥物是 ORLADEYO。他們認為市場上最大的成長會出現在這裡。我想這是因為他們在自己的患者身上看到的治療結果。

  • Operator

    Operator

  • This concludes our question and answer session. I would like to turn the conference back over to Jim Stonehouse for any closing remarks.

    問答環節到此結束。我想把電話會議交回給 Jim Stonehouse,請他做結語。

  • Jon Stonehouse - President, Chief Executive Officer, Director

    Jon Stonehouse - President, Chief Executive Officer, Director

  • Yeah, I'd just like to wrap it up by saying, again, what I said before. It was an absolutely amazing quarter. It's two in a row now. The momentum we have, we see no signs of it slowing down. We're now having revenue over $100 million per quarter. And you should ask yourself, why is this happening? It's because this drug really works, right? When a patient sees control, they have the same kind of control they had with any other prophy medicine they were on before, and they get it with a once daily oral medicine. And that is why we're seeing this great success.

    是的,我想做個總結,再次重申我先前說過的。這是一個非常驚人的季度。而且已經連續兩季了。我們目前的動能,看不到任何放緩的跡象。我們現在每季營收已超過 1 億美元。你應該問自己:為什麼會發生這種情況?因為這個藥真的有效,對吧?當患者看到病情獲得控制,他們能得到與先前使用任何其他預防性藥物相同程度的控制,而且是透過每日一次的口服藥達成。這就是我們看到如此成功的原因。

  • And then the last thing I'd say is thanks to the commercial team for just have an outstanding performance and continuing to build the momentum in this company. Thank you.

    最後我想說的是,感謝商業團隊的傑出表現,並持續為公司建立動能。謝謝。

  • Operator

    Operator

  • This concludes our question and answer session. I would like to thank everybody for joining today's presentation. You may now disconnect.

    問答環節到此結束。感謝各位參加今天的簡報。您現在可以掛線。